本帖最后由 老马 于 2013-3-13 13:43 编辑 2 E- N- |& i8 h% n/ H0 X
" | |! L! o+ C& d
健择（吉西他滨）+顺铂+阿瓦斯汀! R' P8 V2 a1 [, L# F' z
Gemzar +Cisplatin + Avastin& {! C' H" v* ~$ P
http://annonc.oxfordjournals.org/content/21/9/1804.full
5 }( P0 K4 O2 r6 xOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . c0 P3 \. [- s$ [: @ m2 }9 N& ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. * o# t/ p$ q: E9 U0 Q: Z* ?
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 8 B# e4 g# R( V4 i) F( E; w
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
) I8 Y# T' i4 x. k: {& [2 O2 P华为网盘附件：, j. m" @8 w. {" d( C
【华为网盘】ava.JPG$ i; V3 ~0 P/ s, ]* G1 G! W/ U
|
11011102001537 )
显身卡
